These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37768368)

  • 21. Gene Therapy in Hereditary Retinal Dystrophies: The Usefulness of Diagnostic Tools in Candidate Patient Selections.
    Malvasi M; Casillo L; Avogaro F; Abbouda A; Vingolo EM
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gene therapy for vision restoration in patients with Leber congenital amaurosis (LCA) due to RPE65 gene mutations: beginning the phase IV trial].
    Chacón-Camacho ÓF; Zenteno JC
    Gac Med Mex; 2017; 153(2):276-278. PubMed ID: 28474714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene therapy for RPE65-related retinal disease.
    Miraldi Utz V; Coussa RG; Antaki F; Traboulsi EI
    Ophthalmic Genet; 2018 Dec; 39(6):671-677. PubMed ID: 30335549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Voretigene neparvovec-rzyl for treatment of
    Ciulla TA; Hussain RM; Berrocal AM; Nagiel A
    Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacological Amelioration of Cone Survival and Vision in a Mouse Model for Leber Congenital Amaurosis.
    Li S; Samardzija M; Yang Z; Grimm C; Jin M
    J Neurosci; 2016 May; 36(21):5808-19. PubMed ID: 27225770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene therapy for Leber congenital amaurosis: advances and future directions.
    Hufnagel RB; Ahmed ZM; Corrêa ZM; Sisk RA
    Graefes Arch Clin Exp Ophthalmol; 2012 Aug; 250(8):1117-28. PubMed ID: 22644094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Ocular Gene Therapy in an Italian Patient Affected by Congenital Leber Amaurosis Type 2 Treated in Both Eyes.
    Testa F; Maguire AM; Rossi S; Marshall K; Auricchio A; Melillo P; Bennett J; Simonelli F
    Adv Exp Med Biol; 2016; 854():533-9. PubMed ID: 26427456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
    Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
    Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa.
    Kwak JJ; Kim HR; Byeon SH
    Yonsei Med J; 2022 Jul; 63(7):701-705. PubMed ID: 35748082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effect of gene therapy on Leber's congenital amaurosis.
    Bainbridge JW; Mehat MS; Sundaram V; Robbie SJ; Barker SE; Ripamonti C; Georgiadis A; Mowat FM; Beattie SG; Gardner PJ; Feathers KL; Luong VA; Yzer S; Balaggan K; Viswanathan A; de Ravel TJ; Casteels I; Holder GE; Tyler N; Fitzke FW; Weleber RG; Nardini M; Moore AT; Thompson DA; Petersen-Jones SM; Michaelides M; van den Born LI; Stockman A; Smith AJ; Rubin G; Ali RR
    N Engl J Med; 2015 May; 372(20):1887-97. PubMed ID: 25938638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudo-fovea formation after gene therapy for RPE65-LCA.
    Cideciyan AV; Aguirre GK; Jacobson SG; Butt OH; Schwartz SB; Swider M; Roman AJ; Sadigh S; Hauswirth WW
    Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):526-37. PubMed ID: 25537204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence.
    Kolesnikova M; Lima de Carvalho JR; Parmann R; Kim AH; Mahajan VB; Tsang SH; Sparrow JR
    Mol Genet Genomic Med; 2022 Nov; 10(11):e2038. PubMed ID: 36225124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial.
    Koenekoop RK; Sui R; Sallum J; van den Born LI; Ajlan R; Khan A; den Hollander AI; Cremers FP; Mendola JD; Bittner AK; Dagnelie G; Schuchard RA; Saperstein DA
    Lancet; 2014 Oct; 384(9953):1513-20. PubMed ID: 25030840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intervisit variability of visual parameters in Leber congenital amaurosis caused by RPE65 mutations.
    Roman AJ; Cideciyan AV; Schwartz SB; Olivares MB; Heon E; Jacobson SG
    Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1378-83. PubMed ID: 23341016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visual Acuity, Retinal Morphology, and Patients' Perceptions after Voretigene Neparovec-rzyl Therapy for RPE65-Associated Retinal Disease.
    Sengillo JD; Gregori NZ; Sisk RA; Weng CY; Berrocal AM; Davis JL; Mendoza-Santiesteban CE; Zheng DD; Feuer WJ; Lam BL
    Ophthalmol Retina; 2022 Apr; 6(4):273-283. PubMed ID: 34896323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Systematic Review and Meta-Analyses of Interventional Clinical Trial Studies for Gene Therapies for the Inherited Retinal Degenerations (IRDs).
    Tuohy GP; Megaw R
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34069580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RPE65 Mutations in Two Japanese Families with Leber Congenital Amaurosis.
    Katagiri S; Hayashi T; Kondo M; Tsukitome H; Yoshitake K; Akahori M; Ikeo K; Tsuneoka H; Iwata T
    Ophthalmic Genet; 2016 Jun; 37(2):161-9. PubMed ID: 25495949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.
    Lorenz B; Künzel SH; Preising MN; Scholz JP; Chang P; Holz FG; Herrmann P
    Ophthalmology; 2024 Feb; 131(2):161-178. PubMed ID: 37704110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.
    Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Objective Outcomes to Evaluate Voretigene Neparvovec Treatment Effects in Clinical Practice.
    Melillo P; Testa F; Di Iorio V; Karali M; Citro A; Della Corte M; Rossi S; Banfi S; Simonelli F
    Ophthalmol Retina; 2024 Jul; 8(7):688-698. PubMed ID: 38295874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.